cloudfront

Report Detail



Pharmaceuticals & HealthcarePulmonary Embolism - Pipeline Review, H2 2018

  • RnM2315573
  • |
  • 7 August, 2018
  • |
  • Global
  • |
  • 37 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Pulmonary Embolism - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Pulmonary Embolism - Overview

              Pulmonary Embolism - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Pulmonary Embolism - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Pulmonary Embolism - Companies Involved in Therapeutics Development

                                      Accu-Break Pharmaceuticals Inc

                                        Daiichi Sankyo Co Ltd

                                          Dong-A Socio Holdings Co Ltd

                                            F. Hoffmann-La Roche Ltd

                                              Tasly Pharmaceutical Group Co Ltd

                                                Verseon Corp

                                                  Pulmonary Embolism - Drug Profiles

                                                    DS-1040 - Drug Profile

                                                      Product Description

                                                        Mechanism Of Action

                                                          R&D Progress

                                                            Heparin - Drug Profile

                                                              Product Description

                                                                Mechanism Of Action

                                                                  R&D Progress

                                                                    Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile

                                                                      Product Description

                                                                        Mechanism Of Action

                                                                          R&D Progress

                                                                            TRX-1 - Drug Profile

                                                                              Product Description

                                                                                Mechanism Of Action

                                                                                  R&D Progress

                                                                                    urokinase - Drug Profile

                                                                                      Product Description

                                                                                        Mechanism Of Action

                                                                                          R&D Progress

                                                                                            VE-1902 - Drug Profile

                                                                                              Product Description

                                                                                                Mechanism Of Action

                                                                                                  R&D Progress

                                                                                                    VE-2851 - Drug Profile

                                                                                                      Product Description

                                                                                                        Mechanism Of Action

                                                                                                          R&D Progress

                                                                                                            warfarin potassium - Drug Profile

                                                                                                              Product Description

                                                                                                                Mechanism Of Action

                                                                                                                  R&D Progress

                                                                                                                    Pulmonary Embolism - Dormant Projects

                                                                                                                      Pulmonary Embolism - Discontinued Products

                                                                                                                        Pulmonary Embolism - Product Development Milestones

                                                                                                                          Featured News & Press Releases

                                                                                                                            Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

                                                                                                                              Appendix

                                                                                                                                Methodology

                                                                                                                                  Coverage

                                                                                                                                    Secondary Research

                                                                                                                                      Primary Research

                                                                                                                                        Expert Panel Validation

                                                                                                                                          Contact Us

                                                                                                                                            Disclaimer

                                                                                                                                            Pulmonary Embolism - Pipeline Review, H2 2018

                                                                                                                                            Summary

                                                                                                                                            Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

                                                                                                                                            Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

                                                                                                                                            Report Highlights

                                                                                                                                            Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                            The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

                                                                                                                                            Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                            Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                            Scope

                                                                                                                                            - The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
                                                                                                                                            - The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                            - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                            - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                            - The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
                                                                                                                                            - The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                            - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                            - The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

                                                                                                                                            Reasons to buy

                                                                                                                                            - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                            - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                            - Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
                                                                                                                                            - Classify potential new clients or partners in the target demographic.
                                                                                                                                            - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                            - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                            - Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
                                                                                                                                            - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                            - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.




                                                                                                                                            Summary:
                                                                                                                                            Get latest Market Research Reports on Pulmonary Embolism. Industry analysis & Market Report on Pulmonary Embolism is a syndicated market report, published as Pulmonary Embolism - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Pulmonary Embolism market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                                                            Purchase this Report

                                                                                                                                            $2,000.00
                                                                                                                                            $4,000.00
                                                                                                                                            $6,000.00
                                                                                                                                            1,343.00
                                                                                                                                            2,686.00
                                                                                                                                            4,029.00
                                                                                                                                            1,840.40
                                                                                                                                            3,680.80
                                                                                                                                            5,521.20
                                                                                                                                            242,280.00
                                                                                                                                            484,560.00
                                                                                                                                            726,840.00
                                                                                                                                            132,626.80
                                                                                                                                            265,253.60
                                                                                                                                            397,880.40
                                                                                                                                            Add To Cart Credit card Logo

                                                                                                                                            Related Reports


                                                                                                                                            Reason to Buy

                                                                                                                                            Request for Sample of this report